Results 71 to 80 of about 50,237 (216)

Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients

Diagnostics
Upon first exposure to cetuximab, hypersensitivity reactions can occur. We aimed to assess the utility of the basophil activation test (BAT) to alpha-gal and cetuximab for predicting severe reactions.
Peter Kopač, Ana Koren, Urška Bidovec-Stojkovič, Mitja Košnik, Luka Dejanović, Tanja Mesti, Primož Strojan, Peter Korošec, Janja Ocvirk   +8 more
doaj   +1 more source

Distribution of explanatory variables between patients receiving cetuximab and those not receiving cetuximab for propensity score quintiles ranging from 1 (least likely to receive cetuximab) to 5 (most likely to receive cetxuimab).

, 2013
Distribution of explanatory variables between patients receiving cetuximab and those not receiving cetuximab for propensity score quintiles ranging from 1 (least likely to receive cetuximab) to 5 (most likely to receive cetxuimab).
Hsu-Chueh Ho (296931), Tza-Ta Huang (296929), Ching-Chih Lee (113210), Yu-Chieh Su (138988), Pesus Chou (16164), Hon-Yi Lin (296978), Szu-Chin Li (296979), Shih-Hsuan Hsiao (296975)   +7 more
core   +1 more source

The Use of Combination Palliative Radiotherapy and Single‐Agent Immunotherapy for the Management of Head and Neck Squamous Cell Carcinoma (HNSCC) in the United Kingdom (UK)

International Journal of Cancer, EarlyView.
ABSTRACT Clinical data on combined Immunotherapy (IO) and palliative radiotherapy (RT) in HNSCC is scarce. HNSCC Palliative RT differs from curative intent RT as it does not involve elective nodal irradiation; therefore, an immune response may be more likely.
Chris Hurt, Sarah Park, Jonathan Chambers, Caroline Brammer, Matthew Griffin, Vishnu Harilal, Ruth Stone, Puteri Abdul Haris, Rebecca Shakir, Louise Karsera, Will Ince, Femi Adeoye, Daljit Gahir, James Lester, Ehiosa Charles Okuofo, Saira Khalique, Mayumi Forster, Philippa Smith, Oliver Donnelly, Lyndon Ridges‐Jones, James Hesford, Naomi Cole   +21 more
wiley   +1 more source

Cetuximab in Colon Cancer

, 2007
In the last decade remarkable progress has been made in the treatment of metastatic colorectal cancer due to the introduction of oxaliplatin and irinotecan in clinical practice.
F. Giuliani, G. Colucci
core   +1 more source

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

Molecular Oncology, 2018
The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). After initial promising results with EGFR‐targeted therapies such as cetuximab, therapeutic resistance has become a major clinical
Ines De Pauw, Filip Lardon, Jolien Van den Bossche, Hasan Baysal, Erik Fransen, Vanessa Deschoolmeester, Patrick Pauwels, Marc Peeters, Jan Baptist Vermorken, An Wouters   +9 more
doaj   +1 more source

Resistance to Cetuximab in EGFR-Overexpressing Esophageal Squamous Cell Carcinoma Xenografts Due to FGFR2 Amplification and Overexpression

Journal of Pharmacological Sciences, 2014
Esophageal carcinoma is one of the most virulent malignant diseases and a major cause of cancer-related deaths worldwide. Despite improvements in surgical techniques and perioperative management and surgery combined with chemotherapy and/or radiotherapy,
Yi Zhang, Tiecheng Pan, Xiaoxuan Zhong, Cai Cheng   +3 more
doaj   +1 more source

Long‐Term Clinical Response After Low‐Dose and Short‐Duration Cemiplimab Therapy in a Patient With Xeroderma Pigmentosum in Nepal

JEADV Clinical Practice, EarlyView.
Capsule Summary Xeroderma pigmentosum (XP) is associated with a high risk of multiple and aggressive cutaneous squamous cell carcinomas (CSCCs). The immune checkpoint inhibitor cemiplimab has been approved in advanced, unresectable, and/or metastatic CSCCs.
Sudip Parajuli, Arnab Panta, Sabina Bhandari, Anne Grange, Florent Grange, Upama Paudel   +5 more
wiley   +1 more source

Therapeutic Challenges in Managing Coexisting Hidradenitis Suppurativa and Squamous Cell Carcinoma: A Clinical Case Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting intertriginous areas. Long‐standing HS can undergo malignant transformation into squamous cell carcinoma (SCC), particularly in the perineal and gluteal regions. We report a 54‐year‐old man with severe, treatment‐refractory HS complicated by an aggressive verrucous
Michael Zolotas, Tereza Jakovljevicova, Kamran Ghoreschi, Kerstin Kusch, Marisa Klemp, Robert Sabat, Georgios Kokolakis   +6 more
wiley   +1 more source

Novel Functions of Cetuximab In Egfr-Targeted Therapy: Radiosensitization, Glycolysis Inhibition, and Cellular Redox Status Regulation [PDF]

, 2013
Epidermal growth factor receptor (EGFR) is overexpressed in the majority of head and neck cancers. The anti-EGFR antibody cetuximab has been approved by the FDA for the treatment of head and neck cancers, however, only a small fraction of patients ...
Lu, Haiquan
core   +1 more source

Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations

, 2017
Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.
Liang, Yi-Hsin;Lin, Yu-Lin;Liau, Jau-Yu;Tsai, Jia-Huei;Liang, Jin-Tung;Lin, Been-Ren;Hung, Ji-Shiang;Tseng, Li-Hui;Lin, Liang-In;Chang, Yih-Leong;Cheng, Ann-Lii;Yeh, Kun-Huei, 梁逸歆;林亮音;曾麗慧;張逸良;林育麟;鄭安理;葉坤輝;蔡佳惠;洪基翔;林本仁;廖肇裕;梁金銅   +1 more
core